Recent Publications from the Kuliopulos Lab

Research Publications Biochemistry Cell Biology Genetics


Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, Covic L, Kuliopulos A. 2016. Targeting liver fibrosis with a cell-penetrating PAR2 pepducin. J Biol Chem. Epub ahead of print. books

Wieser V, Adolph TE, Enrich B, Kuliopulos A, Kaser A, Tilg H, Kaneider NC. 2016. Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors. Gut Epub ahead of print.  books

Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. 2015. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler Thromb Vasc Biol. 36: 189-197.  books

Zhang P, Covic L, Kuliopulos A. 2015. Pepducins and other lipidated peptides as mechanistic probes and therapeutics. Methods Mol Biol. 1324: 191-203.  books

Yang E, Cisowski J, Nguyen N, O'Callaghan K, Xu J, Agarwal A, Kuliopulos A, Covic L. 2015. Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene 35: 1529-1540. books

Zhang P, Leger AJ, Baleja JD, Rana R, Corlin T, Nguyen N, Koukos G, Bohm A, Covic L, Kuliopulos A. 2015. Allosteric activation of a G protein coupled receptor with cell-penetrating receptor mimetics. J Biol Chem. 290: 15785-15798. books

Gurbel PA, Kuliopulos A, Tantry US. 2015. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol.35: 500-512 . books

Foley CJ, Kuliopulos A. 2014. Mouse matrix metalloprotease-1a (Mmp1a) gives new insight Into MMP function. J Cell Physiol. 229: 1875-1880. books

Austin KM, Nguyen N, Javid G, Covic L, Kuliopulos A. 2013. Non-canonical MMP1-PAR1 signaling triggers vascular smooth muscle cell de-differentiation and arterial stenosis. J Biol Chem. 288: 23105-13115. books

Foley CJ, Fanjul-Fernández M, Bohm A, Nguyen N, Agarwal A, Austin K, Koukos G, Covic L, López-Otín C, Kuliopulos A. 2013. Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. Oncogene 33: 2264-2272. books

Michael ES, Kuliopulos A, Covic L, Steer ML, Perides G. 2013. Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol. 304: G516-G526. books

Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A, Zarwan C, Kim YB, Sharifi S, Agarwal A. 2013. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis and tumor growth in ovarian cancer. Cancer Res. 73: 2457-2467. books

Austin KM, Covic L, Kuliopulos A. 2013. Matrix metalloproteases and PAR1 activation. Blood. 121: 431-439. books

Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A. 2012. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126: 83091. books

Foley CJ, Luo C, O’Callaghan K, Hinds P, Covic L, Kuliopulos A. 2012. Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem. 287: 24330-24338. books

O'Callaghan K, Kuliopulos A, Covic L. 2012. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 287: 12787-12796.books

O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L. 2012. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood. 119: 1717-1725. books

Dimond P, Carlson K, Bouvier M, Gerard C, Xu L, Covic L, Agarwal A, Ernst OP, Janz JM, Schwartz TW, Gardella TJ, Milligan G, Kuliopulos A, Sakmar TP, Hunt SW 3rd. 2011. G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann NY Acad Sci. 1226: 34-49. books

Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K, Agarwal A, Covic L, Opal SM, Kuliopulos A. 2011. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 3: 370-384. books

Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A. 2011. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA 108: 8491-8496. books

Sevigny LM, Austin KM, Zhang P, Kasuda S, Koukos G, Sharifi S, Covic L, Kuliopulos A. 2011. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 31: e100-106. books

Hatziapostolou M, Koukos G, Polytarchou C, Kottakis F, Serebrennikova O, Kuliopulos A, Tsichlis PN. 2011. Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal. 4: ra55. books

Cisowski J, O’Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, Yang E, Fogel M, Tressel S, Foley C, Agarwal A, Hunt III SW, McMurry T, Brinckerhoff L, Covic L. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Amer J Pathol. 179: 513-523. books

Kimmelstiel C, Zhang P, Kapur NK, Weintraub A, Krishnamurthy B, Castaneda V, Covic L, Kuliopulos A. 2011. Bivalirudin Is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 4: 171-179. books

Dowal L, Sim DS, Dilks JR, Blair P, Beaudry S, Denker BM, Koukos G, Kuliopulos A, Flaumenhaft R. 2011.  Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci USA 108: 2951-2956.  books

Tressel SL, Koukos G, Tchernychev B, Jacques SL, Covic L, Kuliopulos A. 2010. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol Biol. 683: 259-275. books

Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L, Kuliopulos A. 2010. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: Implications for antiangiogenic therapy. Cancer Res. 70: 5880-5890. books

Swift S, Xu J, Trivedi V, Austin KM, Tressel SL, Zhang L, Covic L, Kuliopulos A. 2010. A novel protease-activated receptor-1 interactor, Bicaudal D1, regulates G protein signaling and internalization. J Biol Chem. 285: 11402-11410. books

Miller J, Agarwal A, Devi LA, Fontanini K, Hamilton JA, Pin JP, Shields DC, Spek CA, Sakmar TP, Kuliopulos A, Hunt SW 3rd. 2009. Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann NY Acad Sci. 1180 Suppl 1: E1-E12. books

Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, Kuliopulos A, Covic L. 2009. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.. Cancer Res 69: 6223-6231. books

Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A. 2009. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137: 332-343. books

Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquium Participants. 2009. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol. 29: 449-457. books

Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S, Kuliopulos A. 2008. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther. 7: 2746-2757. books

Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A. 2007. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 8: 1303-1312. books

Kaneider NC, Leger AJ, Kuliopulos A. 2006. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J. 273: 4416-4424. books

Leger AJ, Covic L, Kuliopulos A. 2006. Protease-activated receptors in cardiovascular diseases. Circulation 114: 1070-1077. books

Nguyen N, Kuliopulos A, Graham RA, Covic L. 2006. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res. 66: 2658-2665. books

Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. 2006. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113: 1244-1254. books

Swift S, Leger AJ, Talavera J, Zhang L, Bohm A, Kuliopulos A. 2006. Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. J Biol Chem. 281: 4109-4116. books

Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. 2005. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med. 11: 661-665. books

Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A. 2005. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res. 116: 55-65. books

Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313. books

Apply to the Sackler School


The priority application deadlines are as follows:

December 1: Basic Science Division PhD Programs

February 15: Building Diversity in Biomedical Sciences

March 31: Post-Baccalaureate Research Program

May 1: Clinical & Translational Science, MS in Pharmacology & Drug Development

June 15: Online Certificate in Fundamentals of Clinical Care Research